

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code : 2666)

UNAUDITED OPERATION SUMMARY OF THE GROUP FOR THE FIRST QUARTER OF 2023

This announcement sets out the unaudited operation summary of Genertec Universal Medical Group Company Limited (the “**Company**”), together with its subsidiaries (the “**Group**”), for the first quarter ended 31 March 2023.

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

During the first quarter of 2023, the Group promoted business development of all sectors: the operating revenue of the Group increased by approximately 21.8% as compared with the corresponding period of 2022, the profit for the period decreased by approximately 10.4% as compared with the corresponding period of 2022, and the profit for the period attributable to ordinary shareholders of the parent decreased by approximately 15.6% as compared with the corresponding period of 2022, mainly due to the significant increase in the cost of foreign currency borrowings of the finance business compared to the first quarter of 2022 (as the Federal Reserve has not raised the interest rate in the first quarter of 2022 yet), resulting in profit of finance business for the period decreased by approximately 18.8%.

In respect of hospital group business, the member medical institutions managed by the Group were greatly influenced by the external environment in the first quarter of last year, and their effectiveness has been improved in the past year: the revenue of hospital group business increased by approximately 56.0% as compared with the corresponding period of 2022, and the profit for the period increased more significantly as compared with the corresponding period of 2022. Focusing on the primary goals of “comfortable environment, top-notch services, advanced technology and efficient operation”, the

Group continued to empower the development of the hospitals run by state-owned enterprises and constantly improve operation efficiency and effectiveness. In terms of hospital operation excluding the impact of newly consolidated medical institutions, total number of outpatient and emergency visits increased by approximately 18.1% as compared with the corresponding period of 2022; visits for medical examination increased by approximately 5.6% as compared with the corresponding period of 2022; the number of inpatients increased by approximately 29.7% as compared with the corresponding period of 2022. In addition, with the business foundation and professional core talent team of our own hospital group, the work of specialties and healthy industry operation is conducted as scheduled, and the self-expansion business and external mergers and acquisitions are also progressing smoothly.

In respect of finance business, with risk control as the top priority and promoting the investment of interest-generating assets in an orderly manner, the Group was committed to ensuring quality project development for customers. By keeping abreast of the market changes, the Group strived to arrange financing structure properly, so as to ensure liquidity conditions while trying to absorb the cost impact of a higher interest rate environment abroad. As at 31 March 2023, interest-earning assets continued to increase as compared with the end of 2022, net interest margin and net interest spread both decreased slightly due to the impact of foreign financing costs, asset quality still remained at a good level, and the provision coverage remained prudent.

In addition, references are made to the Company's announcements dated 19 May 2020, 8 April 2021, 16 September 2021, 20 December 2021, 30 May 2022, 6 July 2022, 5 September 2022 and 13 January 2023 in relation to the issuance of the medium-term notes with an aggregate principal amount of RMB4.00 billion in the inter-bank market in the People's Republic of China (the "PRC") by China Universal Leasing Co., Ltd. (中國環球租賃有限公司) ("Universal Leasing"), a wholly-owned subsidiary of the Company. In accordance with the relevant laws and regulations of the PRC, the unaudited consolidated financial information of Universal Leasing for the three months ended 31 March 2023 (the "Universal Leasing Consolidated Financial Information") has been published on the websites of Shanghai Clearing House (www.shclearing.com) and China Foreign Exchange Trade System (www.chinamoney.com.cn) on 27 April 2023. The Company's board of directors would like to draw the attention of its shareholders and investors to the following principal financial data of Universal Leasing:

PRINCIPAL CONSOLIDATED FINANCIAL DATA OF UNIVERSAL LEASING

*Unit: Thousand Yuan
Currency: RMB*

	As at 31 March 2023 (unaudited)	As at 31 December 2022 (audited)
Total assets	83,501,402	76,507,178
Total equity	20,297,378	20,476,986
	For the three months ended 31 March 2023 (unaudited)	For the three months ended 31 March 2022 (unaudited)

Operating income	3,243,589	2,664,252
Profit for the period	471,731	527,750
Net cash flows (used in) operating activities	(5,733,987)	(4,297,548)

The Company hereby reminds investors that the above unaudited operation summary for the first quarter ended 31 March 2023 was prepared based on the Group's internal figures and management accounts which have not been reviewed or audited by the auditors of the Group. The Universal Leasing Consolidated Financial Information was prepared in accordance with the General Accepted Accounting Principles of the PRC, which may require adjustment during the course of auditing of the financial results of the Group, and the information contained therein is limited solely to the operation of Universal Leasing, which does not provide a full picture of the operation status of the Group or comparison with the Group.

Investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
**Genertec Universal Medical Group Company
Limited**
通用環球醫療集團有限公司
Peng Jiahong
Chairwoman of the Board

Beijing, PRC, 27 April 2023

As at the date of this announcement, the executive directors of the Company are Ms. Peng Jiahong (Chairwoman), Mr. Wang Wenbing and Mr. Yu Gang; the non-executive directors of the Company are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.